Imfinzi + EV approved in US in bladder cancer

Summary by AI BETAClose X

AstraZeneca's Imfinzi plus enfortumab vedotin received US FDA approval as a perioperative regimen for cisplatin-ineligible or cisplatin-refusing muscle-invasive bladder cancer after VOLGA Phase III data showing a 49% reduction in risk of progression/recurrence (EFS HR 0.51; 95% CI 0.38–0.67; p<0.0001) and a 42% reduction in risk of death (OS HR 0.58; 95% CI 0.40–0.83; p=0.0027); median EFS and OS were not reached versus 12.1 months EFS for the comparator, two‑year event‑free rates were 64% versus 45% and two‑year OS was 78% versus 69%, while Grade 3–4 adverse events occurred in 64% versus 44%; US approval via Priority Review targets ~16,000 MIBC patients in 2026 and EU/Japan reviews are ongoing.

Disclaimer*

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings